Patents by Inventor Elizabeth M. Doherty
Elizabeth M. Doherty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11806346Abstract: Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.Type: GrantFiled: May 12, 2021Date of Patent: November 7, 2023Assignee: CHDI Foundation, Inc.Inventors: Celia Dominguez, Elizabeth M. Doherty, Longbin Liu, Matthew Lee, Mark Stuart Chambers, Karine Fabienne Malagu, Perla Breccia, Alan F. Haughan, Huw D. Vater, Andrew J. Stott, William R. K. Esmieu, Stephen John Webster, Amanda J. Van De Poël
-
Publication number: 20220409615Abstract: Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.Type: ApplicationFiled: May 12, 2021Publication date: December 29, 2022Inventors: Celia Dominguez, Elizabeth M. Doherty, Longbin Liu, Matthew Lee, Mark Stuart Chambers, Karine Fabienne Malagu, Perla Breccia, Alan F. Haughan, Huw D. Vater, Andrew J. Stott, William R. K. Esmieu, Stephen John Webster, Amanda J. Van De Poël
-
Patent number: 10344060Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: GrantFiled: March 12, 2014Date of Patent: July 9, 2019Assignee: AMGEN INC.Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda, Kaustav Biswas, Bin Wu, Kelvin Sham, Jason C. Long
-
Patent number: 9636418Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: GrantFiled: March 12, 2014Date of Patent: May 2, 2017Assignee: AMGEN INC.Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda
-
Publication number: 20160067347Abstract: The application is directed to APJ receptor agonist analogs having increased stability relative to the wild type apelin-13 and methods of using the agonist analogs. The analogs can be used, inter alia, in cardiac disorders such as heart failure.Type: ApplicationFiled: December 17, 2013Publication date: March 10, 2016Applicant: AMGEN INC.Inventors: Jerry Ryan HOLDER, Gayathri SWAMINATH, Leslie P. MIRANDA, Jennifer ARAL, Elizabeth M. DOHERTY, Thomas NIXEY
-
Publication number: 20160024159Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: January 28, 2016Applicant: AMGEN INC.Inventors: Justin K. MURRAY, Jerry Ryan HOLDER, Malgorzata WANSKA, Christopher M. TEGLEY, James R. FALSEY, Elizabeth M. DOHERTY, Leslie P. MIRANDA, Kaustav BISWAS, Bin WU, Kelvin SHAM, Jason C. LONG
-
Publication number: 20150023988Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: January 22, 2015Applicant: AMGEN INC.Inventors: Justin K. MURRAY, Jerry Ryan HOLDER, Malgorzata WANSKA, Christopher M. TEGLEY, James R. FALSEY, Elizabeth M. DOHERTY, Leslie P. MIRANDA
-
Patent number: 8716281Abstract: The present invention describes pyrimidine compounds of Formula I that are useful as anaplastic lymphoma kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: GrantFiled: May 4, 2011Date of Patent: May 6, 2014Assignee: Amgen Inc.Inventors: Marian C. Bryan, Alan C. Cheng, Elizabeth M. Doherty, James R. Falsey, Ingrid M. Fellows, Joseph L. Kim, Richard T. Lewis, Michele H. Potashman, Douglas A. Whittington
-
Publication number: 20140005198Abstract: The present invention comprises a new class of compounds capable of modulating the activity of Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I wherein each of A1, A2, A3, A4, A5, A6, A7, A8, A9, bond B, X, rings Z1 and Z2, R1 and R3 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.Type: ApplicationFiled: August 28, 2013Publication date: January 2, 2014Applicant: AMGEN INC.Inventors: Adrian L. SMITH, Elizabeth M. DOHERTY, Qi HUANG, Gang LIU
-
Patent number: 8557830Abstract: The present invention comprises a new class of compounds capable of modulating the activity of Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula (I) wherein each of A1, A2, A3, A4, A5, A6, A7, A8, A9, bond B, X, rings Z1 and Z2, R1 and R3 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.Type: GrantFiled: June 5, 2008Date of Patent: October 15, 2013Assignee: Amgen Inc.Inventors: Adrian L. Smith, Elizabeth M. Doherty, Qi Huang, Gang Liu
-
Publication number: 20130158019Abstract: Compounds of Formula I are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.Type: ApplicationFiled: May 4, 2011Publication date: June 20, 2013Applicant: AMGEN INC.Inventors: Marian C. Bryan, Alan C. Cheng, Elizabeth M. Doherty, James R. Falsey, Ingrid M. Fellows, Joseph L. Kim, Richard T. Lewis, Michele H. Potashman, Douglas A. Whittington
-
Patent number: 8440674Abstract: The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I wherein R1 is and A1, A2, A3, A4, X, Z, Z?, R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.Type: GrantFiled: June 17, 2011Date of Patent: May 14, 2013Assignee: Amgen Inc.Inventors: Frenel F. De Morin, Jian J. Chen, Elizabeth M. Doherty, Stephen A. Hitchcock, Qi Huang, Joseph L. Kim, Gang Liu, Thomas Nixey, Nick A. Paras, Jeffrey Petkus, Daniel Martin Retz, Adrian Leonard Smith, Jiawang Zhu
-
Patent number: 8227469Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, dType: GrantFiled: April 2, 2009Date of Patent: July 24, 2012Assignee: Amgen Inc.Inventors: Chenera Balan, Ning Chen, Elizabeth M. Doherty, Vijay Keshav Gore, Mark H. Norman, Hui-Ling Wang
-
Publication number: 20110251199Abstract: The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I and A1, A2, A3, A4, X, Z, Z?, R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.Type: ApplicationFiled: June 17, 2011Publication date: October 13, 2011Applicant: Amgen Inc.Inventors: Frenel F. De Morin, Jian J. Chen, Elizabeth M. Doherty, Stephen Hitchcock, Qi Huang, Joseph L. Kim, Gang Liu, Thomas Nixey, Nick A. Paras, Jeffrey Petkus, Daniel M. Retz, Adrian L. Smith, Jiawang Zhu
-
Publication number: 20100324047Abstract: The present invention comprises a new class of compounds capable of modulating the activity of Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula (I) wherein each of A1, A2, A3, A4, A5, A6, A7, A8, A9, bond B, X, rings Z1 and Z2, R1 and R3 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.Type: ApplicationFiled: June 5, 2008Publication date: December 23, 2010Applicant: AMGEN INC.Inventors: Adrian L. Smith, Elizabeth M. Doherty, Qi Huang, Gang Liu
-
Publication number: 20090264424Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, dType: ApplicationFiled: June 26, 2009Publication date: October 22, 2009Inventors: Yunxin Y. Bo, Partha P. Chakrabarti, Ning Chen, Elizabeth M. Doherty, Christopher H. Fotsch, Nianhe Han, Michael G. Kelly, Qingyian Liu, Mark Henry Norman, Vassil I. Ognyanov, Xianghong Wang, Jiawang Zhu
-
Patent number: 7582657Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, dType: GrantFiled: December 10, 2002Date of Patent: September 1, 2009Assignee: Amgen Inc.Inventors: Ning Chen, Elizabeth M. Doherty, Michael G. Kelly
-
Patent number: 7579347Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, dType: GrantFiled: April 5, 2005Date of Patent: August 25, 2009Assignee: Amgen Inc.Inventors: Yunxin Y. Bo, Partha P. Chakrabarti, Ning Chen, Elizabeth M. Doherty, Christopher H. Fotsch, Nianhe Han, Michael G. Kelly, Qingyian Liu, Mark Henry Norman, Vassil I. Ognyanov, Xianghong Wang, Jiawang Zhu
-
Publication number: 20090197879Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, dType: ApplicationFiled: April 2, 2009Publication date: August 6, 2009Inventors: Chenera Balan, Ning Chen, Elizabeth M. Doherty, Vijay Keshav Gore, Mark H. Norman, Hui-Ling Wang
-
Patent number: 7534798Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, dType: GrantFiled: February 11, 2005Date of Patent: May 19, 2009Assignee: Amgen Inc.Inventors: Chenera Balan, Ning Chen, Elizabeth M. Doherty, Vijay Keshav Gore, Mark H. Norman, Hui-Ling Wang